Advicenne: Net Revenue More Than Doubled to €2.7M in H1 2026
Advicenne announced a net revenue of €2.7M for the first half of 2026, up from €1.03M a year earlier. This significant increase is mainly due to the pricing agreements for Sibnayal® and Likozam®, which ended the early access discounts that had impacted the H1 2025 revenue by €1.6M. The company also indicated it has a cash runway until the second quarter of 2027, thanks to the bond financing announced on June 22, 2026.
Significant Revenue Increase Due to the End of Early Access Discounts
Advicenne reported a net revenue of €2.7M in the first half of 2026, an increase from the first half of 2025. This growth is primarily attributed to the pricing agreements for Sibnayal® and Likozam®, which concluded the early access discounts. These discounts had a negative impact of €1.6M in the first half of 2025 and no longer affect the accounts for the first half of 2026. The release highlights that this is the first period where the revenue is not burdened by this significant negative impact.
Sales Volumes Continue to Grow
Since the reimbursement approval of Sibnayal® and Likozam® in France, sales volumes have increased by 41% and 13% respectively. Sibnayal®'s sales across all its marketing territories reached €6.6M in the first half of 2026, up 27% from the first half of 2025, reflecting, according to Advicenne, the steady increase in the number of treated patients. Royalties from these sales will be received by Advicenne during the third quarter of 2026.
A Cash Runway Until the Second Quarter of 2027
As of the date of the announcement, Advicenne has a cash runway until the second quarter of 2027, thanks to the implementation of the bond financing announced on June 22, 2026, as part of the safeguard procedure.
